medicinal chemistry

August 7, 2017

Vanderbilt begins Phase 1 trials of new Alzheimer’s drug

Developed at Vanderbilt, VU319 is designed to precisely target a specific neuron receptor associated with cognitive function while avoiding potentially dangerous side effects.

By Bill Snyder

March 19, 2014

Small molecule protects kidney filter

A compound identified at Vanderbilt has therapeutic potential in protecting the kidney filter barrier.